Home Metabolism Factor Xa

Factor Xa

Choose Selective Factor Xa Inhibitors

Factor Xa Signaling Pathway Map

Factor Xa Signaling Pathways

Factor Xa Products

  • All (8)
  • Factor Xa Inhibitors (8)
  • New Factor Xa Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1346 Heparin sodium Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins. Heparin is used as an anticoagulant primarily through its interaction with AT III by enhancing AT-IIImediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin prevents the induction of autophagy.
J Extracell Vesicles, 2021, 10(8):e12091
Nat Struct Mol Biol, 2021, 10.1038/s41594-020-00537-7
Theranostics, 2021, 11(5):2364-2380
S1593 Apixaban (BMS 562247-01) Apixaban (BMS 562247-01) is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
PLoS One, 2022, 17(1):e0262482
Neural Regen Res, 2021, 16(10):2086-2092
Int J Mol Sci, 2020, 31;21(7):2422
S3002 Rivaroxaban (BAY 59-7939) Rivaroxaban (BAY 59-7939) is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM).
PLoS One, 2022, 17(1):e0262482
Br J Pharmacol, 2021, 10.1111/bph.15681
J Thromb Haemost, 2020, 18(8):1866-1873
S3736 Fondaparinux Sodium (Org 31540) Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
S4429New Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
J Thromb Haemost, 2020, 18(8):1866-1873
bioRxiv, 2020, 10.1101/2020.04.22.054981
S5388 Betrixaban Betrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S5389 Betrixaban maleate Betrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S7280 Edoxaban tosylate Monohydrate Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
J Thromb Haemost, 2020, 18(8):1866-1873
J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1146:122121
Viruses, 2020, 10;12(6):E629
S1346 Heparin sodium Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins. Heparin is used as an anticoagulant primarily through its interaction with AT III by enhancing AT-IIImediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin prevents the induction of autophagy.
J Extracell Vesicles, 2021, 10(8):e12091
Nat Struct Mol Biol, 2021, 10.1038/s41594-020-00537-7
Theranostics, 2021, 11(5):2364-2380
S1593 Apixaban (BMS 562247-01) Apixaban (BMS 562247-01) is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
PLoS One, 2022, 17(1):e0262482
Neural Regen Res, 2021, 16(10):2086-2092
Int J Mol Sci, 2020, 31;21(7):2422
S3002 Rivaroxaban (BAY 59-7939) Rivaroxaban (BAY 59-7939) is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM).
PLoS One, 2022, 17(1):e0262482
Br J Pharmacol, 2021, 10.1111/bph.15681
J Thromb Haemost, 2020, 18(8):1866-1873
S3736 Fondaparinux Sodium (Org 31540) Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
S4429New Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
J Thromb Haemost, 2020, 18(8):1866-1873
bioRxiv, 2020, 10.1101/2020.04.22.054981
S5388 Betrixaban Betrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S5389 Betrixaban maleate Betrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S7280 Edoxaban tosylate Monohydrate Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
J Thromb Haemost, 2020, 18(8):1866-1873
J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1146:122121
Viruses, 2020, 10;12(6):E629
S4429New Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
J Thromb Haemost, 2020, 18(8):1866-1873
bioRxiv, 2020, 10.1101/2020.04.22.054981